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IMPORTANCE Social and occupational impairments contribute to the burden of psychosis and
depression. There is a need for risk stratification tools to inform personalized
functional-disability preventive strategies for individuals in at-risk and early phases of these
illnesses.
OBJECTIVE To determine whether predictors associated with social and role functioning can
be identified in patients in clinical high-risk (CHR) states for psychosis or with recent-onset
depression (ROD) using clinical, imaging-based, and combinedmachine learning; assess the
geographic, transdiagnostic, and prognostic generalizability of machine learning and compare
it with human prognostication; and explore sequential prognosis encompassing clinical and
combinedmachine learning.
DESIGN, SETTING, AND PARTICIPANTS This multisite naturalistic study followed up patients in
CHR states, with ROD, and with recent-onset psychosis, and healthy control participants for
18months in 7 academic early-recognition services in 5 European countries. Participants were
recruited between February 2014 andMay 2016, and data were analyzed from April 2017 to
January 2018.
AIN OUTCOMES ANDMEASURES Performance and generalizability of prognostic models.
RESULTS A total of 116 individuals in CHR states (mean [SD] age, 24.0 [5.1] years; 58 [50.0%]
female) and 120 patients with ROD (mean [SD] age, 26.1 [6.1] years; 65 [54.2%] female) were
followed up for a mean (SD) of 329 (142) days. Machine learning predicted the 1-year
social-functioning outcomes with a balanced accuracy of 76.9% of patients in CHR states and
66.2% of patients with ROD using clinical baseline data. Balanced accuracy in models using
structural neuroimaging was 76.2% in patients in CHR states and 65.0% in patients with ROD,
and in combinedmodels, it was 82.7% for CHR states and 70.3% for ROD. Lower functioning
before study entry was a transdiagnostic predictor. Medial prefrontal and temporo-parieto-
occipital gray matter volume (GMV) reductions and cerebellar and dorsolateral prefrontal
GMV increments had predictive value in the CHR group; reducedmediotemporal and
increased prefrontal-perisylvian GMV had predictive value in patients with ROD. Poor
prognoses were associated with increased risk of psychotic, depressive, and anxiety
disorders at follow-up in patients in the CHR state but not ones with ROD. Machine learning
outperformed expert prognostication. Adding neuroimagingmachine learning to clinical
machine learning provided a 1.9-fold increase of prognostic certainty in uncertain cases of
patients in CHR states, and a 10.5-fold increase of prognostic certainty for patients with ROD.
CONCLUSIONS AND RELEVANCE Precisionmedicine tools could augment effective therapeutic
strategies aiming at the prevention of social functioning impairments in patients with CHR
states or with ROD.
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R ecent research has extended the scope of early recog-nitionandpreventionofpsychosisbeyonddisease tran-sition to poor outcomes more broadly.1-5 This is be-
cause the clinical high-risk (CHR) state for psychosis, present
in2%to 10%ofyouth,6maybe linkedwithnonpsychoticmor-
bidity encompassing mood, anxiety, and substance use
disorders.3Moreover, theCHR state frequently entails persis-
tent neurocognitive and functional deficits,whichmay cause
the affected young persons to increasingly lag behind their
peers in a critical phase of personal development.7-9 Prospec-
tive research has demonstrated that these deficits, in combi-
nation with clinical and sociodemographic risk factors, fore-
shadowpoor clinical outcomes.9-13 Similarly, adolescents and
young adults who experience a first major affective episode
are not only at risk for relapse but frequently have persistent
functional deficits, depressive symptoms, and reduced qual-
ity of life, as is often seen in patients in the CHR state.14 These
shared impairments6,15 may point to a common neurobio-
logical surrogate predating the disabling outcomes of these
conditions. Such a marker of brain pathology could accu-
rately estimate the risk for functional deficits, thus informing
risk-adapted preventive interventions in these vulnerable
persons.
Previous research suggested that psychosis can be pre-
dicted in individual patients in CHR states who are recruited
in researchcontexts12,16-20 andsecondaryhealthcare settings21
through the use of clinical, neurocognitive, neurophysiologi-
cal, and magnetic resonance imaging (MRI) data. This preci-
sion medicine approach has been further strengthened by
machine-learning studies showing that clinical baseline data
may be associated with predictors of functional and treat-
ment outcomes in first-episode psychosis and depression
across multiple sites.22-24 Proof-of-concept studies have also
suggested that global functioning of the CHR state can be in-
dividually approximated by MRI-based models.25,26 How-
ever, thepredictabilityof functional outcomes shouldbe sepa-
rately assessed for the social and role functioning domains
because thesemaybedifferentially linked to symptoms, neu-
rocognitive deficits, and adverse outcomes; for instance, dis-
organization and processing speed may be associated with
predictors of social disability (which in turn is associatedwith
transition to psychosis), whilemotor disturbances and verbal
fluencymaybe linkedwithoccupationaldisability.7,12,27,28Fur-
thermore,predictabilityshouldbecomparedacrosspartlyover-
lapping clinical syndromes, such as the CHR state and major
depressive disorder, and benchmarked in large, geographi-
cally diverse cohorts of vulnerable persons.29
Although it has been conceptually suggested, the ques-
tion of whether behavioral andMRI-based data could be effi-
ciently combined within sequential prognostic algorithms to
optimize predictive power has yet to be empirically tested.30
The clinical implementationof such algorithmsdoesnot only
depend on the evidence for their generalizability, but also on
the accuracy margin between models and the practices of
health care professionals.31 Only if a conservative estimate of
this margin indicates that clinical reasoning could be en-
hanced in termsofprecision, time, andcostswouldcomputer-
aided decision support in clinical settings be justified.31-33 Fi-
nally, validated predictors associatedwith specific outcomes
couldprovide resource allocation tools for existingpsychoso-
cial interventions,34-36 and foster biobehavioral mechanistic
research leading to new personalized and preventive treat-
ments for social and occupational disability.37
To develop such prognostic signatures, the Personalized
Prognostic Tools for Early Psychosis Management (PRONIA;
https://www.pronia.eu/) study is collecting multimodal data
fromhealthycontrolparticipantsandyoungpatientswhomeet
criteria for the CHR state, recent-onset psychosis, or recent-
onset depression (ROD). In this first study, we test the geo-
graphic generalizability of functional, neuroanatomical, and
combined machine-learning models, tasked with predicting
the 1-year social and role functioning of patients in the CHR
state and patients with ROD recruited in 5 European coun-
tries.We estimate themodels’ transdiagnostic transferability
and their associationswith prognostic generalizability across
diagnosticandpsychometricoutcomedomains, compare them
with the prognostic estimates provided by clinical raters, and
explore sequential prognostic algorithmscombingclinical and
imaging-based models.
Methods
Thestudymethodsaredetailed in theeMethods in theSupple-
ment. We analyzed patients with CHR or ROD who were re-
cruitedusing internationallyestablisheddiagnosticcriteria,and
forwhombaselineMRIand follow-upsocial and role function-
ing scoreswere available between the 3-month and 12-month
pointsof the study (eFigure 1 in theSupplement).Additionally,
wematchedhealthcontrolparticipants individuallyforsite,age,
andsex to theparticipants in theclinical groups (eTable 1 in the
Supplement). Recruitment took place at 7 sites in 5 countries:
the Departments of Psychiatry of the Ludwig-Maximilian-
University inMunich,Bavaria,Germany;UniversityofCologne
inCologne,NorthRhineland–Westphalia,Germany;University
of Turku, Turku, Finland; University of Basel, Basel, Switzer-
land;University ofUdine,Udine, Italy; the Institute ofMental
Key Points
Question Can we develop accurate predictionmodels for future
social and occupational disability in individuals in clinical high-risk
states of psychosis or with recent-onset depression?
Findings Machine-learning predictionmodels trained on
functional, neuroimaging, and combined baseline data correctly
determined social outcomes at 1 year in up to 83% of patients in
clinical high-risk states and 70% of patients with recent-onset
depression across geographically distinct populations but could
not accurately determine role-functioning outcomes. Models
outperformed human prognostication and provided a prognostic
proxy for broader psychiatric morbidity in patients in clinical
high-risk states for psychosis.
Meaning If further validated, these predictive models could
inform the personalized prevention of functional impairment in
patients in clinical high-risk states and patients with recent-onset
depression.
PredictionModels of Functional Outcomes for the Clinical High-Risk State for Psychosis or Recent-Onset Depression Original Investigation Research
jamapsychiatry.com (Reprinted) JAMAPsychiatry November 2018 Volume 75, Number 11 1157
© 2018 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Universita degli di Milano User  on 11/26/2019
HealthatUniversityofBirmingham,Birmingham,England;and
4 recruitment hospitals associated with the University of
Milan,Milan, Italy (Niguarda, Policlinico, San Paolo, andVilla
San Benedetto Menni in Albese con Cassano; eTable 2 in the
Supplement). Participants were recruited between February
2014 andMay 2016 and followed up using a standarized lon-
gitudinal studyprotocol (eFigure 1 in the Supplement). Based
on this protocol, theywere examined using a comprehensive
clinical,neuropsychological,andneuroimagingprotocol(eTables
3 and 4 in the Supplement). Inclusion and exclusion criteria
are detailed in the eMethods and eTable 5 of the Supplement.
A Consolidated Standards of Reporting Trials flowchart of the
patientsstudiedhere isprovidedineFigure2oftheSupplement.
All adultparticipantsprovided theirwritten informedcon-
sentprior to study inclusion.Minorparticipants (definedat all
sites as those younger than 18 years) provided written in-
formed assent and their guardians, written informed con-
sent. The study was registered at the German Clinical Trials
Register (DRKS00005042) and approved by the local re-
search ethics committees in each location.
The Global Functioning: Social and Global Functioning:
Role scales7,10wereused todefine goodvs impaired social and
role functioning at a threshold of more than 7 points (good)
vs 7 or fewer points (impaired), using the participants’ latest
examination within the 3-month to 12-month follow-up pe-
riod. This cutoff demarcates a mild but already persistent or
frequent social-functioning or role-functioning impairment.
Regular interrater reliability tests were performed to cali-
brate the Global Functioning scales across study sites (eTable
6 in the Supplement). The distributions of Global Function-
ing Social andRole scores at baseline and follow-upare shown
in eFigure 3 in the Supplement, and their changes over time
were analyzed in eFigure 4 in the Supplement.
Our machine-learning software, NeuroMiner (version
0.998;https://www.pronia.eu/neurominer/),wasused to train
3 types of models to predict these outcomes (eFigure 2 in the
Supplement). The first used theparticipants’ 8baseline global
functioning social and role scores (including each patient’s
highest lifetime score, highest or lowest score in the past
year, and current social and role Global Functioning Scale
scores).Thesecondmodelanalyzedgraymattervolume(GMV)
images. The third model combined the former 2 models’
outputs into a single result.38 The models were geographi-
cally validated using nested leave-site-out cross-validation.
Further validation analyses assessed the influence of image
quality (eFigure 5 in the Supplement), follow-up interval
variations (eFigure6 in theSupplement), site-associatedvaria-
tions (eFigure 7 and eTable 7 in the Supplement), and base-
line social functioning variations (eTable 8 in the Supple-
ment). Voxel-basedmorphometric (VBM) analyses compared
thepatternsof associationofpredictors inpatient groupswith
theneuroanatomicalvariationof thesamples fromthematched
healthy control participants (eFigures 8 and 9 in the Supple-
ment). Details of structural MRI (sMRI) sequence parameters
are in eTable 4 in the Supplement.
The reliability ofMRI-based and clinical predictions feed-
ing into combinedmodelswasmeasuredvia a cross-validation
ratioprofile (CVR = mean(w)/standarderror(w),wherew is the
normalizedweightvectorof the support-vectormachinemod-
els generated in the study’s nested leave-site-out cross-
validation setup. Normalization was performed using the
Euclidean norm of w, defined as s=w/||w||2.39
Models were compared with each other and with expert
raters’ prognostic performance (eTable 9 in the Supplement).
Thenumberof raters is indeterminate, because thehealth care
professionalswho rated eachpatientwerenot recorded in the
central database for security reasons.
Furthermore,we testedmodel transferabilitybetween the
2 clinical groups and assessed their prognostic generaliz-
ability to outcomes beyond social functioning, including
(1) transition to psychosis, (2) mood, anxiety, and substance-
associated DSM-IV-TR diagnoses at the follow-up exam-
ination 9 months after study entry (eTable 10 in the Supple-
ment), and (3)multivariatepatterns40of clinical and functional
changes between baseline and follow-up (eFigure 10 in the
Supplement). We also explored whether the outcome prob-
ability estimates providedby the sMRI-based social function-
ing predictor could be used for the prediction of the ordinal
GF scores (eMethods and eFigure 11 in the Supplement). Fi-
nally, we assessed prognostic algorithms sequentially com-
bining clinical and sMRI-based models (eFigures 12 and 13 in
the Supplement).
Permutation testing was used to assess the models’ sta-
tistical significance, which was defined as a P value less than
.05 (further details in the eMethods in the Supplement). The
false-detection rate was used to correct the P values of mul-
tiple comparisonswith respect todescriptive statistics, leave-
site-out analyses, and assessments of transdiagnostic gener-
alizability. Descriptive univariate analyses were carried out
usingSPSSversion23 (IBM).Dataanalysiswascompleted from
April 2017 to January 2018.
Results
Group-Level Sociodemographic and Clinical
Differences at Baseline
We recruited a total of 116 patients in the CHR state and 120
patientswith ROD. In addition, we recruited 176 healthy con-
trol participants who were matched to the respective patient
groups by age, site, and sex (eTable 1 in the Supplement).
The sociodemographic characteristics of patients in CHR
states who had impaired social functioning at follow-up did
not differ significantly from those of patients with unim-
paired outcomes. However, patients in CHR states with im-
paired role functioning outcomes showed more eductional
problems in termsofeducational years repeated (patientswith
impaired outcomes: mean [SD], 0.5 [1.0] years; patients with
unimpaired outcomes: mean [SD], 0.1 [0.3] years; P = .01;
Table 1). Compared with patients with ROD who were unim-
paired at follow-up, patientswithRODwhohad impairedout-
comes had a younger mean (SD) age (patients with impaired
social-functioning outcomes: 24.6 [5.6] years; patients with
unimpaired social-functioning outcomes: 28.0 [6.2] years;
P = .01; patients with impaired role-functioning outcomes:
24.5 [5.5] years; patients with unimpaired role-functioning
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Table 1. Study-Associated, Sociodemographic, Physical, Clinical, and Functional Differences at Baseline in Individuals in Clinical High-Risk States
and IndividualsWith Recent-Onset DepressionWith Impaired vs Unimpaired Social-Functioning and Role-Functioning Outcomes at Follow-up
Characteristic
Follow-up
Clinical High-Risk Group Recent-Onset Depression Group
Impaired Unimpaired t/z/χ2 P Value Impaired Unimpaired t/z/χ2 P Value
Social Functioning
Sample sizes and study
variables
Total No. 66 50
χ 27 = 16.4
65 55
Participants per site,
No. (%)
.03 χ 26 = 3.10 .95
Munich 22 (33) 11 (22) 22 (34) 17 (31)
Milan 5 (8) 1 (2) 2 (3.0) 2 (4)
Basel 4 (6) 11 (22) 6 (9) 8 (15)
Cologne 10 (15) 9 (18) 12 (18) 9 (16)
Birmingham 3 (5) 9 (18) 5 (8) 8 (15)
Turku 14 (21) 5 (10) 8 (12) 4 (7)
Udine 8 (12) 4 (8) 10 (15) 7 (13)
Interval between MRI
and clinical examination,
mean (SD), d
343.7 (146.7) 333.3 (158.6) t114 = 0.37 .80 312.6
(141.0)
327.3
(125.5)
t118 = 0.60 .69
Participants examined
postenrollment, No. per
month
χ 23 = 4.84 .29 χ 23 = 1.71 >.99
3 2 1 7 3
6 2 7 4 3
9 43 29 44 37
12 19 13 10 12
Sociodemographic data
Age, mean (SD), y 23.6 (4.7) 24.5 (5.5) t114 = −1.00 .46 24.6 (5.6) 28.0 (6.2) t118 = −3.10 .01
Male, No. (%) 34 (51.5) 24 (48.0) χ 21 = 0.14 .91 30 (46.2) 25 (45.5) χ 21 = 0.01 >.99
Edinburgh Handedness
Score, mean (SD)
58.1 (61.7) 70.7 (54.6) t105 = −1.10 .41 77.2 (42.9) 78 (39.2) t110 = −0.11 >.99
Education, mean (SD), y 13.3 (2.5) 14.3 (3.5) t114 = −1.71 .17 14.2 (2.9) 16.1 (3.0) t117 = −3.49 .01
Educational years
repeated, mean (SD), y
0.5 (0.9) 0.2 (0.5) t114 = 2.23 .08 0.2 (0.6) 0.5 (1.2) t115 = −1.18 .34
Having a partnership
most of the time in the
year before study
inclusion, No. (%)
30 (45.5) 29 (58.0) χ 21 = 1.79 .32 29 (44.6) 40 (72.7) χ 21 = 9.63 .01
Population density in
living area, mean (SD),
habitants/km2
2876.5 (2314.2) 3229.1
(2470.9)
t114 = −0.79 .57 2773.0
(2401.3)
3375.4
(2212.4)
t118 = −1.42 .25
Clinical high-risk state
inclusion criteria
Schizotypal personality
disorder present,
No. (%)
6 (9.1) 0 χ 21 = 4.79 .09 0 0 NA NA
First-degree relatives
with psychosis, No. (%)
5 (7.6) 10 (20.0) χ 21 = 3.90 .13 2 (3.1) 1 (1.8) χ 21 = 0.19 <.99
30% Loss of global
functioning compared
with highest levels in the
year before study
inclusion, No. (%)
34 (51.5) 18 (36.0) χ 21 = 2.77 .23 13 (20.0) 7 (12.7) χ 21 = 1.14 .45
Genetic Risk Disability
Schizotypal Personality
Disorder Criterion
criteria met, No. (%)
7 (10.6) 8 (16.0) χ 21 = 0.74 .56 NA NA NA NA
Cognitive Disturbances
criteria met, No. (%)
34 (51.5) 31 (62.0) χ 21 = 1.27 .49 NA NA NA NA
Attenuated Psychotic
Symptoms criteria met,
No. (%)
42 (63.6) 30 (60.0) χ 21 = 0.16 .79 NA NA NA NA
Brief Limited
Intermittent Psychotic
Symptoms criteria met,
No. (%)
2 (3.0) 2 (4.0) χ 21 = 0.08 >.99 NA NA NA NA
(continued)
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Table 1. Study-Associated, Sociodemographic, Physical, Clinical, and Functional Differences at Baseline in Individuals in Clinical High-Risk States
and IndividualsWith Recent-Onset DepressionWith Impaired vs Unimpaired Social-Functioning and Role-Functioning Outcomes at Follow-up
(continued)
Characteristic
Follow-up
Clinical High-Risk Group Recent-Onset Depression Group
Impaired Unimpaired t/z/χ2 P Value Impaired Unimpaired t/z/χ2 P Value
Global Assessment of
Functioning score at
baseline, mean (SD)
Disability, highest
lifetime score
78.1 (8.5) 82.1 (6.9) t114 = −2.71 .03 78.7 (8.7) 83.3 (7.2) t118 = −3.17 .01
Symptoms, highest
lifetime score
78.8 (8.5) 80.6 (8.4) t114 = −1.14 .39 81 (7.2) 83.5 (7.1) t118 = −1.87 .14
Disability, score in
past year
64.8 (13.1) 72.1 (10.4) t114 = −3.25 .01 68.2 (14.5) 75.2 (11.6) t118 = −2.87 .02
Symptoms, score in
past year
64.3 (12.1) 69.6 (10.4) t114 = −2.49 .04 70.7 (12.7) 73.5 (11.2) t118 = −1.29 .30
Disability, score in
past month
52.5 (11.7) 60.2 (14.9) t114 = −2.99 .02 52.2 (13.4) 61.4 (14.6) t118 = −3.57 .01
Symptoms, score in
past month
53.2 (11) 57.5 (10.5) t114 = −2.12 .09 53.1 (11.5) 58.2 (12.5) t118 = −2.32 .06
Global Functioning:
Social scale, mean (SD)
score
Highest lifetime
score
7.5 (0.8) 8.3 (0.6) z = −5.24 <.001 7.8 (0.9) 8.4 (0.8) z = −3.69 <.001
Highest score in
past year
6.7 (1.4) 7.8 (0.7) z = −5.55 <.001 6.9 (1.4) 7.7 (0.8) z = −3.69 <.001
Baseline score 6 (1.3) 7.1 (1.1) z = −4.51 <.001 5.9 (1.5) 6.9 (1.0) z = −4.15 <.001
Global Functioning: Role
scale, mean (SD) score
Highest lifetime
score
7.8 (0.9) 8.2 (0.8) z = −2.64 .03 8 (0.8) 8.6 (0.8) z = −3.47 .01
Highest score in
past year
6.8 (1.3) 7.6 (0.9) z = −3.40 .01 7.3 (1.1) 7.9 (1.1) z = −3.30 .01
Baseline 5.7 (1.4) 6.7 (1.2) z = −3.83 <.001 5.9 (1.7) 6.8 (1.4) z = −3.09 .01
Standardized Interview
for Prodromal
Symptoms score at
baseline, mean (SD)
scores
Unusual thought
content or delusional
ideas
2.36 (1.65) 2.56 (1.61) z = −0.64 .63 0.97 (1.06) 0.93 (0.96) z = 0.23 .95
Suspiciousness or
Persecutory ideas
1.91 (1.91) 1.86 (1.87) z = 0.14 .93 0.17 (0.45) 0.31 (0.74) z = −1.22 .33
Grandiosity 0.38 (0.97) 0.28 (0.78) z = 0.59 .65 0.06 (0.30) 0.00 (0.00) z = 1.66 .19
Perceptual
abnormalities
1.85 (1.92) 2.06 (1.45) z = −0.68 .63 0.68 (0.94) 0.80 (1.21) z = −0.63 .67
Disorganized
communication
0.95 (1.47) 0.76 (1.14) z = 0.78 .57 0.25 (0.64) 0.09 (0.35) z = 1.69 .18
Social anhedonia 2.36 (1.75) 1.18 (1.57) z = 3.76 <.001 2.18 (1.90) 1.40 (1.61) z = 2.42 .05
Avolition 2.55 (1.64) 2.00 (1.59) z = 1.80 .15 2.60 (1.67) 2.22 (1.61) z = 1.28 .30
Expression of emotion 1.30 (1.59) 0.62 (1.19) z = 2.65 .03 1.12 (1.42) 0.55 (1.00) z = 2.61 .03
Experience of
emotions and self
1.50 (1.55) 1.22 (1.61) z = 0.95 .49 1.26 (1.42) 1.24 (1.60) z = 0.09 >.99
Ideational richness 0.76 (1.50) 0.14 (0.50) z = 3.15 .01 0.35 (0.99) 0.05 (0.30) z = 2.36 .06
Occupational
functioning
2.97 (1.91) 1.90 (1.73) z = 3.12 .01 2.62 (1.74) 2.07 (1.73) z = 1.71 .18
Beck Depression
Inventory sum score
25.3 (11.1) 22.4 (11.0) t106 = 1.32 .32 23.8 (12.5) 23.9 (12.6) t111 = −0.50 >.99
Positive and Negative
Syndrome Scale, mean
(SD) scores
Total 52.9 (15.2) 46.7 (10.1) t112 = 2.62 .03 49.5 (10.3) 44.0 (9.6) t117 = 3.00 .01
Positive sum 10.1 (3.0) 10.1 (3.1) t113 = −0.10 .94 7.6 (1.1) 7.6 (1.1) t117 = −0.11 >.99
Negative sum 14.6 (6.6) 9.8 (3.6) t113 = 4.93 <.001 13.6 (5.2) 11.1 (4.0) t117 = 2.94 .02
General sum 28.3 (7.7) 26.8 (5.9) t112 = 1.20 .36 28.3 (6.4) 25.4 (6.2) t117 = 2.58 .04
(continued)
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Table 1. Study-Associated, Sociodemographic, Physical, Clinical, and Functional Differences at Baseline in Individuals in Clinical High-Risk States
and IndividualsWith Recent-Onset DepressionWith Impaired vs Unimpaired Social-Functioning and Role-Functioning Outcomes at Follow-up
(continued)
Characteristic
Follow-up
Clinical High-Risk Group Recent-Onset Depression Group
Impaired Unimpaired t/z/χ2 P Value Impaired Unimpaired t/z/χ2 P Value
Role Functioning
Sample sizes and study
variables
Total No. 69 47 64 56
Participants per site,
No. (%)
χ 27 = 12.4 .12 χ 26 = 1.8 >.99
Munich 21 (30) 12 (26) 22 (34) 17 (30)
Milan 5 (7) 1 (2) 3 (5) 1 (2)
Basel 5 (7) 10 (21) 7 (11) 7 (13)
Cologne 12 (17) 7 (15) 10 (16) 11 (20)
Birmingham 4 (6) 8 (17) 6 (9) 7 (13)
Turku 15 (22) 4 (9) 6 (9) 6 (11)
Udine 7 (10) 5 (11) 10 (16) 7 (13)
Interval between MRI and
clinical examination,
mean (SD), d
338.3 (158.2) 340.5
(142.3)
t114 = 0.08 .95 301.1
(135.8)
340.1
(129.5)
t118 = −1.60 .19
Participants examined
postenrollment, No. per
month
χ 23 = 2.89 .59 χ 23 = 3.40 .46
3 3 0 7 3
6 4 5 5 2
9 43 29 43 38
12 19 13 9 13
Sociodemographic data
Age, mean (SD), y 23.7 (4.9) 24.4 (5.3) t114 = −0.68 .61 24.5 (5.5) 28 (6.2) t118 = −3.30 .01
Male, No. (%) 36 (52.2) 22 (46.8) χ 21 = 0.32 .79 31 (48.4) 24 (42.9) χ 21 = 0.38 .72
Edinburgh Handedness
Score, mean (SD)
55.9 (66.3) 75.3 (43.5) t105 = −1.83 .15 78.2 (37.7) 76.9 (44.6) t110 = 0.18 .98
Education, mean (SD), y 13.4 (2.5) 14.1 (3.5) t114 = −1.22 .36 14.3 (3.0) 15.8 (3.1) t117 = −2.62 .03
Educational years
repeated, mean (SD), y
0.5 (1.0)a 0.1 (0.3)a t114 = 3.01 .01 0.3 (0.6) 0.4 (1.2) t115 = −1.07 .40
Having a partnership most
of the time in the year
before study inclusion,
No. (%)
33 (47.8) 26 (55.3) χ 21 = 0.63 .59 32 (50.0) 37 (66.1) χ 21 = 3.16 .18
Population density in
living area, mean (SD),
habitants/km2
2916.2 (2265.8) 3193.3
(2552)
t114 = −0.61 .64 3032.7
(2422.3)
3067.9
(2234)
t118 = −0.08 >.99
Clinical high-risk state
inclusion criteria
Schizotypal personality
disorder present, No. (%)
5 (7.2) 1 (2.1) χ 21 = 1.49 .54 0 0 NA NA
First-degree relatives
with psychosis, No. (%)
4 (5.8) 11 (23.4) χ 21 = 7.7 .03 2 (3.1) 1 (1.8) χ 21 = 0.22 >.99
30% Loss of global
functioning compared
with highest levels in the
year before study
inclusion, No. (%)
36 (52.2) 16 (34.0) χ 21 = 3.72 .13 14 (21.9) 6 (10.7) χ 21 = 2.68 .23
Genetic Risk Disability
Schizotypal Personality
Disorder Criterion criteria
met, No. (%)
6 (8.7) 9 (19.1) χ 21 = 2.71 .27 NA NA NA NA
Cognitive Disturbances
criteria met, No. (%)
38(55.1) 27 (57.4) χ 21 = 0.06 .91 NA NA NA NA
Attenuated Psychotic
Symptoms criteria met,
No. (%)
47 (49.3) 25 (53.2/ ) χ 21 = 2.65 .22 NA NA NA NA
Brief Limited Intermittent
Psychotic Symptoms
criteria met, No. (%)
1 (1.4) 3 (6.4) χ 21 = 2.04 .45 NA NA NA NA
(continued)
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outcomes: 28 [6.2] years; P = .01) and fewer years of educa-
tion (patientswith impairedsocial-functioningoutcomes: 14.2
[2.9] years; patients with unimpaired social-functioning out-
comes: 16.1 [3.0] years; P = .01; patients with impaired role-
functioning outcomes: 14.3 [3.0] years; patients with unim-
paired role-functioning outcomes: 15.8 [3.1] years; P = .03).
Table 1. Study-Associated, Sociodemographic, Physical, Clinical, and Functional Differences at Baseline in Individuals in Clinical High-Risk States
and IndividualsWith Recent-Onset DepressionWith Impaired vs Unimpaired Social-Functioning and Role-Functioning Outcomes at Follow-up
(continued)
Characteristic
Follow-up
Clinical High-Risk Group Recent-Onset Depression Group
Impaired Unimpaired t/z/χ2 P Value Impaired Unimpaired t/z/χ2 P Value
Global Assessment of
Functioning score at
baseline, mean (SD)
Disability, highest lifetime
score
78.7 (9) 81.5 (6.2) t114 = −1.98 .12 79.2 (9) 82.7 (7) t118 = −2.36 .06
Symptoms, highest
lifetime score
78.7 (8.7) 80.8 (8.1) t114 = −1.30 .32 81.2 (7.2) 83.3 (7.2) t118 = −1.55 .20
Disability, score in past
year
66 (13.5) 70.8 (10.5) t114 = −2.02 .1 67.9 (14.3) 75.3 (11.7) t118 = −3.07 .01
Symptoms, score in past
year
64.6 (12.5) 69.6 (9.7) t114 = −2.30 .07 70.3 (12.5) 73.9 (11.3) t118 = −1.63 .19
Disability, score in past
month
52.6 (12.1) 60.5 (14.5) t114 = −3.19 .01 51.9 (13.0) 61.6 (14.8) t118 = −3.85 <.001
Symptoms, score in past
month
53.4 (10.8) 57.5 (10.7) t114 = −1.98 .12 53.3 (11.5) 58 (12.5) t118 = −2.14 .08
Global Functioning: Social
scale, mean (SD) score
Highest lifetime score 7.7 (0.9) 8.2 (0.7) z = −3.14 .01 7.9 (0.9) 8.3 (0.9) z = −2.80 .02
Highest score in past
year
6.9 (1.4) 7.6 (0.8) z = −2.87 .02 7.0 (1.4) 7.6 (1.0) z = −2.15 .08
Baseline score 6.2 (1.4) 6.9 (1.1) z = −2.54 .03 6.0 (1.5) 6.8 (1.3) z = −3.21 .01
Global Functioning: Role
scale, mean (SD) score
Highest lifetime score 7.8 (0.9) 8.3 (0.7) z = −3.80 <.001 8.1 (0.8) 8.5 (0.8) z = −2.78 .01
Highest score in past
year
6.8 (1.2) 7.7 (0.9) z = −4.29 <.001 7.3 (1.1) 7.9 (1.2) z = −3.10 .01
Baseline 5.6 (1.2) 6.9 (1.3) z = −4.93 <.001 5.9 (1.7) 6.8 (1.5) z = −2.60 .03
Standardized Interview for
Prodromal Symptoms score
at baseline, mean (SD)
scores
Unusual thought content
or delusional ideas
2.39 (1.67) 2.53 (1.57) z = −0.41 .75 1.05 (1.03) 0.84 (0.99) z = 1.12 .37
Suspiciousness or
Persecutory ideas
1.87 (1.84) 1.91 (1.98) z = −0.13 .93 0.23 (0.66) 0.23 (0.54) z = 0.02 >.99
Grandiosity 0.35 (0.94) 0.32 (0.84) z = 0.17 .92 0.03 (0.18) 0.04 (0.27) z = −0.11 >.99
Perceptual abnormalities 1.97 (1.85) 1.89 (1.56) z = 0.24 .89 0.77 (0.96) 0.70 (1.19) z = 0.35 .87
Disorganized
communication
1.04 (1.46) 0.62 (1.09) z = 1.80 .15 0.27 (0.65) 0.07 (0.32) z = 2.12 .09
Social anhedonia 2.09 (1.73) 1.51 (1.79) z = 1.74 .17 2.17 (1.86) 1.43 (1.67) z = 2.29 .06
Avolition 2.58 (1.56) 1.91 (1.68) z = 2.19 .09 2.64 (1.53) 2.18 (1.74) z = 1.55 .20
Expression of emotion 1.17 (1.59) 0.77 (1.24) z = 1.55 .22 1.11 (1.43) 0.57 (1.01) z = 2.41 .05
Experience of emotions
and self
1.49 (1.56) 1.21 (1.6) z = 0.94 .49 1.34 (1.42) 1.14 (1.59) z = 0.73 .61
Ideational richness 0.72 (1.46) 0.15 (0.51) z = 3.01 .01 0.31 (0.94) 0.11 (0.45) z = 1.55 .20
Occupational functioning 3.25 (1.70) 1.43 (1.65) z = 5.73 <.001 2.7 (1.71) 1.98 (1.73) z = 2.29 .06
Beck Depression Inventory
sum score
25.6 (11.2) 21.9 (10.7) z = 1.71 .17 23 (11.9) 24.7 (13.3) z = −0.70 .63
Positive and Negative
Syndrome Scale, mean (SD)
scores
Total 52.9 (14.9) 46.4 (10.1) t112 = 2.79 .03 48.7 (10.2) 44.9 (10.2) t117 = 2.04 .10
Positive sum 10.3 (3.0) 9.9 (3.0) t113 = 0.70 .61 7.6 (1.2) 7.5 (1.0) t117 = 0.49 .76
Negative sum 14.1 (6.8) 10.1 (3.6) t113 = 4.12 <.001 13.2 (5.0) 11.4 (4.6) t117 = 1.98 .11
General sum 28.5 (7.6) 26.4 (6.1) t112 = 1.55 .22 27.9 (6.5) 25.9 (6.3) t117 = 1.67 .18
Abbreviations: MRI, magnetic resonance imaging; NA, not applicable.
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Impaired social functioning at follow-upwas associatedwith
a lower likelihood of having a partner at baseline in patients
with ROD (impaired social functioning: 29 of 65 [44.6%]; un-
impaired social-functioning: 40 of 55 [72.7%]; P = .01).
Across study groups, impaired social-functioning out-
comeswere associatedwith lowerGlobalAssessmentofFunc-
tioning disability scores in the month before study inclusion
(patients inCHRstates:mean [SD]GlobalAssessmentofFunc-
tioning disability scores, impaired at follow-up: 52.5 [11.7];
unimpaired at follow-up: 60.2 [14.9]; P = .02; patients with
ROD: mean [SD] scores, impaired at follow-up: 52.5 [13.4];
unimpaired at follow-up: 61.4 [14.6]; P = .01). Furthermore,
impaired social functioning at follow-up was associated with
reduced social functioning at baseline (patients in CHR
states: mean [SD] scores, impaired at follow-up: 6.0 [1.3];
unimpaired at follow-up: 7.1 [1.1]; P < .001; patients with
ROD: mean [SD] scores, impaired at follow-up: 5.9 [1.5];
unimpaired at follow-up: 6.9 [1.0]; P < .001), and reduced
global role functioning at baseline (patients in CHR states:
mean [SD] scores, impaired at follow-up: 5.7 [1.4]; unim-
paired at follow-up: 6.7 [1.2]; P < .001; patients with ROD:
mean [SD] scores, impaired at follow-up: 5.9 [1.7]; unim-
paired at follow-up: 6.8 [1.4]; P = .01).
Thesedifferencesextended to the social functioning in the
past year (patients in CHR states: mean [SD] scores, impaired
at follow-up: 6.7 [1.4]; unimpaired at follow-up: 7.8 [0.7];
P < .001; patients with ROD: impaired at follow-up: 6.9 [1.4];
unimpaired at follow-up: 7.7 [0.8]; P < .001) and lifetime so-
cial functioning (patients inCHRstates:mean [SD] scores, im-
pairedat follow-up:7.5 [0.8];unimpairedat follow-up:8.3 [0.6];
P < .001; patients with ROD: impaired at follow-up: 7.8 [0.9];
unimpaired at follow-up: 8.4 [0.8]; P < .001).
At the level of psychopathology, we observed transdiag-
nostic baselinedifferencesbetweengroupswith impairedand
unimpaired outcomes in social functioning in the attenuated
negative symptoms domain, particularly an item in the Stan-
dardized Interview for Prodromal Symptoms (SIPS) scale spe-
cific to expression of emotions (patients in CHR states: mean
[SD] scores, impaired at follow-up: 1.3 [1.6]; unimpaired at
follow-up: 0.6 [1.2]; P = .03; patients with ROD: mean [SD]
scores, impaired at follow-up: 1.1 [1.4]; unimpaired at follow-
up: 0.6 [1.0]; P = .03). Further differences were measured in
thePositive andNegativeSyndromeScale (PANSS) total scores
at baseline (patients in CHR states: mean [SD] scores, im-
paired at follow-up: 52.9 [15.2]; unimpaired at follow-up: 46.7
[10.1];P = .03; patientswithROD: impaired at follow-up: 49.5
[10.3];unimpairedat follow-up:44.0 [9.6];P = .01), andPANSS
negative symptoms scores at baseline (patients inCHRstates:
mean [SD] scores, impaired at follow-up: 14.6 [6.6]; unim-
paired at follow-up: 9.8 [3.6];P < .001; patientswithROD: im-
paired at follow-up: 13.6 [5.2]; unimpaired at follow-up: 11.1
[4.0]; P = .02).
Similar but less pronounced effects were observed in the
role functioning outcome analyses of patients who were
impaired and unimpaired, with the patients in CHR states
who were impaired at follow-up being more affected in the
social functioning at baseline (patients in CHR states: mean
[SD] scores, impaired at follow-up: 6.2 [1.4]; unimpaired at
follow-up: 6.9 [1.1]; P = .03; patients with ROD: mean [SD]
scores, impaired at follow-up: 6.0 [1.5]; unimpaired at follow-
up: 6.8 [1.3]; P = .01), role functioning at baseline (patients in
CHR states: mean [SD] scores, impaired at follow-up: 5.6
[1.2]; unimpaired at follow-up: 6.9 [1.3]; P < .001; patients
with ROD: mean [SD] scores, impaired at follow-up: 5.9 [1.7];
unimpaired at follow-up: 6.8 [1.5]; P = .03). Significantly
more severe baseline negative and PANSS total symptoms
were found in the patients in CHR states who showed role
functioning impairments at follow-up compared with those
who were unimpaired (SIPS assessment of ideational rich-
ness: mean [SD] scores, impaired at follow-up: 0.7 [1.5];
unimpaired at follow-up: 0.2 [0.5]; P = .01; SIPS assessment
of occupational functioning: impaired at follow-up: 3.3 [1.7];
unimpaired at follow-up: 1.4 [1.7]; P < .001; PANSS total
score: impaired at follow-up: 52.9 [14.9]; unimpaired at
follow-up: 46.4 [10.1]; P = .03; PANSS negative score:
impaired at follow-up: 14.1 [6.8]; unimpaired at follow-up:
10.1 [3.6]; P < .001).
Currentmood, anxiety, and substanceusediagnoseswere
prevalent at baseline in the CHR group (33 of 51 patients
[64.7%])andRODgroup(42of49 [85.7%])butdidnotdifferbe-
tween outcome-defined samples (eTable 11 in the Supple-
ment). During the follow-up period, symptomatic diagnoses
declined,but less so in thegroupswhowere impairedat follow-
up: at least 1DSM-IVdiagnosiswas present in 27 of 62 patients
in CHR states whowere impaired at follow-up (44%) and in 25
of52patientswithRODwhowere impairedat follow-up (48%),
comparedwith 4 of 39 patients in CHR states whowere unim-
paired at follow-up (10%) and 12 of 48 patients with RODwho
were unimpaired at follow-up (25%) (eTable 11 in the Supple-
ment).Theseeffectsweredrivenbycurrentdepressionandwere
independentof transition topsychosis (whichoccurred in8pa-
tients in CHR states and 2 patients with ROD; eTable 12 in the
Supplement). Finally,weobserveda significant interactionbe-
tween study sites and social-functioning outcomes in the pa-
tients inCHRstates (with the sample size per site of patients in
CHR stateswhowere impaired at follow-upvarying from22of
33 [66%] inMunich to5of6 [83%] inMilan, 4of 15 [27%] inBa-
sel, 10 of 19 [53%] in Cologne, 3 of 12 [25%] in Birmingham, 14
of 19 [74%] inTurku, and8of 12 [67%] inUdine, and thesample
size per site of patients in CHR states whowere unimpaired at
follow-up ranging from 11 [33%] inMunich to 1 [17%] inMilan,
11 [73%] in Basel, 9 [47%] in Cologne, 9 [75%] in Birmingham,
5 [26%] in Turku, and 4 [33%] in Udine; P = .03 for groupwise
comparison, Table 1). This interaction motivated additional
MRI-based validation analyses, as described in the eMethods,
eFigure 7, and eTable 7 in the Supplement.
Machine-Learning Analyses
Themodels evaluating the patients’ social and role function-
ing at and before study inclusion estimated the social-
functioning outcomes of patients in CHR stateswith a signifi-
cant leave-site-out balanced accuracy of 76.9% (sensitivity:
69.7%; specificity: 84.0%; P = .002 after false-detection rate
adjustment;Table2).Balancedaccuracyof thegroupwithROD
was66.1%,with a sensitivity of 63.1%and specificity of 69.1%
(P = .049; Table 2).
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In thepatients inCHRstates, amodel predicting role func-
tioning scoreswas also significant andperformed at balanced
accuracy of 67.7% (sensitivity: 60.9%; specificity: 74.5%;
P = .02). Clinical models outperformed the sMRI prediction
model in their transdiagnostic transferability (Table3).The fea-
turesmost useful for themodel predicting social functioning
outcome scores in the patients with ROD were Global Func-
tioning Scale scores at baseline, reduced Global Functioning
Scale scores in the year before study inclusion and reduced
Global Functioning Scale scores over the lifetime (Figure 1). In
the group in CHR states, the most useful features were a re-
duced social functioning score in the year before study inclu-
sion and a reduced highest global functioning score over the
lifetime (Figure 1).
Table 2. Leave-Site-Out Classification Performance of Clinical, Imaging-Based, and CombinedMachine-Learning Predictors of Global Functioning
Social Scales or Global Functioning Role Scale Outcomes in Individuals in a Clinical High-Risk and IndividualsWith Recent-Onset Depressiona
Leave-Site-Out
Performance Sensitivity, % Specificity, %
Balanced
Accuracy, %
Positive
Predictive
Value, %
Negative
Predictive
Value, %
Prognostic
Summary
Index
Area
Under
Curve
P Value
for
Model R 2
P Value
for Global
Functioning
Social
functioning
Group in
clinical
high-risk
state
Clinical
model
69.7 84.0 76.9 85.2 67.7 52.9 0.80 .002 0.344 <.001
sMRI model 80.3 72.0 76.2 79.1 73.5 52.6 0.78 .002 0.224 <.001
Combined
model
83.3 82.0 82.7 85.9 78.9 64.8 0.86 <.001 0.402 <.001
Expert
prognosis
51.5 92.0 71.8 89.5 59.0 48.4 0.72 NA NA NA
Group with
recent-onset
depression
Clinical
model
63.1 69.1 66.1 70.7 61.3 32.0 0.72 .04 0.190 <.001
sMRI model 64.6 65.5 65.0 68.9 61.0 29.9 0.70 .04 0.079 .002
Combined
model
76.9 63.6 70.3 71.4 70.0 41.4 0.77 .01 0.228 <.001
Expert
rater
prognosis
26.6 92.6 59.6 81.0 51.5 32.5 0.60 NA NA NA
Role functioning
Group in
clinical
high-risk
state
Clinical
model
60.9 74.5 67.7 77.8 56.5 34.2 0.70 .02 0.178 <.001
sMRI model 66.7 46.8 56.7 64.8 48.9 13.7 0.64 .12 0.138 <.001
Combined
model
59.4 70.2 64.8 74.6 54.1 28.6 0.73 .07 0.267 <.001
Expert
prognosis
49.3 91.5 70.4 89.5 55.1 44.6 0.70 NA NA NA
Group with
recent-onset
depression
Clinical
model
59.4 55.4 57.4 60.3 54.4 14.7 0.65 .15 0.135 <.001
sMRI model 51.6 58.9 55.3 58.9 51.6 10.5 0.62 .15 0.027 .08
Combined
model
60.9 64.3 62.6 66.1 59.0 25.1 0.67 .05 0.106 <.001
Expert
rater
prognosis
25.0 90.7 57.9 76.2 50.5 26.7 0.58 NA NA NA
Abbreviations: CHR, clinical high-risk (state); NA, not available;
ROD, recent-onset depression; sMRI, structural magnetic resonance imaging.
a Across all machine-learningmodels assessed, positive vs negative predictions
defined impaired functional outcomes (defined by Global Functioning Scale
scores7) vs unimpaired functional outcomes (defined by Global Functioning
Scale scores >7). Model significance was determined by 1000 random label
permutations and corrected groupwise for multiple comparisons using the
false-discovery rate.
b Coefficients of determination between the outcome probability estimates and
the patients’ Global Functioning Scale scores at follow-up were assessed for
significance using 2-tailed P values, corrected by the false-discovery rate.
Additionally, the expert rater prognoses regarding the study participants’
global functioning outcomes were compared with the Global Functioning
Scale outcome labels, and respective prediction performances were
calculated.
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The sMRI-based prediction models determined social-
functioning outcomes in the CHR groups with a balanced ac-
curacy of 76.2% (sensitivity: 80.3%, specificity: 72.0%;
P = .002; Table 2). The sMRI-based prediction models deter-
mined social functioning in the patients with RODwith a bal-
anced accuracy of 65.0%, a sensitivity of 64.6%, and a speci-
ficity of 65.5% (P = .04). The performance of models was not
influencedbysite effects (eTable 7andeFigure7 in theSupple-
ment), follow-up duration (eFigure 6 in the Supplement), or
baseline functionaldifferencesbetweenoutcomeclasses (eFig-
ure 8 in the Supplement). In contrastwith the social function-
ing domain, sMRI data could not be used to accurately esti-
mate role-functioning outcomes (Table 2).
Divergent neuroanatomical patterns (Figure 2) impeded
the sMRI model transfer between study groups (Table 3). In
the group in CHR states, social functioning impairments at
follow-up were associated with (1) reduced baseline GMV in
medial prefrontal, cingulate, orbitofrontal, insular, temporal,
parietal, andoccipital brain regions, and (2) increased cerebel-
lar,dorsomedial, anddorsolateralprefrontalGMVs (Figure2A).
To understand whether this signature represented a pattern
ofneuroanatomical abnormality,we compared theprognostic
Table 3. Transdiagnostic Generalizability of Clinical, Structional Magnetic Resonance Imaging–Based and CombinedModelsa
Social-Functioning
Outcomes
True
Positive,
No.
True
Negative,
No.
False
Positive,
No.
False
Negative,
No.
Sensitivity,
%
Specificity,
%
Balanced
Accuracy,
%
Positive
Predictive
Value, %
Negative
Predictive
Value, %
Prognostic
Summary
Index
Area
Under
Curve
P Value
for
Model
Clinical models
Transdiagnostic
performance
80 83 22 51 61.1 79.1 70.1 78.4 61.9 40.4 0.76 .03
ROD→CHR
performance
42 43 7 24 63.6 86.0 74.8 85.7 64.2 49.9 0.82 .03
CHR→ROD
performance
38 40 15 27 58.5 72.7 65.6 71.7 59.7 31.4 0.72 .16
sMRI models
Transdiagnostic
performance
82 58 47 49 62.6 55.2 58.9 63.6 54.2 17.8 0.61 .10
ROD→CHR
performance
46 25 25 20 69.7 50.0 59.9 64.8 55.6 20.3 0.60 .15
CHR→ROD
performance
36 33 22 29 55.4 60.0 57.7 62.1 53.2 15.3 0.62 .16
Combined models
Transdiagnostic
performance
89 69 36 42 67.9 65.7 66.8 71.2 62.2 33.4 0.75 .03
ROD→CHR
performance
46 32 18 20 69.7 64.0 66.9 71.9 61.5 33.4 0.76 .16
CHR→ROD
performance
43 37 18 22 66.2 67.3 66.7 70.5 62.7 33.2 0.75 .09
Role functioning
outcomes
Clinical models
Transdiagnostic
performance
75 76 27 58 56.4 73.8 65.1 73.5 56.7 30.3 0.67 .03
ROD→CHR
performance
41 38 9 28 59.4 80.9 70.1 82.0 57.6 39.6 0.71 .04
CHR→ROD
performance
34 38 18 30 53.1 67.9 60.5 65.4 55.9 21.3 0.64 .14
sMRI models
Transdiagnostic
performance
82 53 50 51 61.7 51.5 56.6 62.1 51.0 13.1 0.58 .14
ROD→CHR
performance
46 22 25 23 66.7 46.8 56.7 64.8 48.9 13.7 0.56 .16
CHR→ROD
performance
36 31 25 28 56.3 55.4 55.8 59.0 52.5 11.6 0.59 .27
Combined models
Transdiagnostic
performance
81 71 32 52 60.9 68.9 64.9 71.7 57.7 29.4 0.69 .03
ROD→CHR
performance
44 28 19 25 63.8 59.6 61.7 69.8 52.8 22.7 0.70 .16
CHR→ROD
performance
37 43 13 27 57.8 76.8 67.3 74.0 61.4 35.4 0.68 .03
Abbreviations: CHR, clinical high-risk [state]; ROD, recent-onset depression;
sMRI, structural magnetic resonance imaging.
a Models were first trained on the ROD group and then applied to the CHR
sample. Then the CHR group served as the optimization sample while the ROD
group was used as validation cohort. The ensemble-based decision scores of
the respective validation sample were used tomeasure transdiagnostic and
directed out-of-sample performances. Transdiagnostic and directedmodel
significances were assessed by computing the prognostic summary index in
1000 random label permutations and comparing them to the observed
prognostic summary index of the respective model. P values were adjusted for
multiple comparisons using the false-discovery rate.
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samples in CHR states to the data frommatched healthy con-
trol participants. The reductions in GMV and increments that
wereassociatedwith impairedsocial-functioningoutcomesdif-
ferentiated patients in CHR states who had a poor prognosis
(defined as a poor outcome predicted by the model, as dis-
tinct from observed impairment at follow-up) from healthy
control participants (eFigure 8 in the Supplement).
Different fromthegroup inCHRstates, theneuroanatomi-
cal patternassociatedwith social-functioningoutcomes inpa-
tients with ROD included (1) reduced GMV in the hippocam-
pus, amygdala, inferior temporal cortex, thalamus, anddorsal
anterior cingulate cortex, and (2) increased GMV in the me-
dial and lateral prefrontal, orbitofrontal, insular, and supe-
rior temporal cortices.TheseGMVincrements,butnot the tem-
porolimbic reductions, were encountered again when
comparingpatientswithRODandpoorprognoseswithhealthy
control participants using VBM (eFigure 9 in the Supple-
ment). In contrast, patients with ROD and unimpaired social
functioningprognosis showedreducedprefrontalGMVand in-
creased temporolimbic GMV compared with healthy control
participants.
Combinedmodels predicting social functioning scores es-
timated the outcomes of patients in CHR states with a bal-
ancedaccuracyof82.7%(sensitivity:83.2%;specificity:82.0%;
P < .001; Table 2). The same models estimated outcomes of
patients with ROD with a balanced accuracy of 70.3% (sensi-
tivity: 76.9%; specificity: 63.6%; P = .01). The combined
models’ prognostic summary index (PSI) outperformed the
sMRI-based models’ PSI by 12.2% in the CHR group (sMRI
model: 52.6%; combinedmodel: 64.8%) and 11.5% in theROD
group (sMRImodel: 29.9%;combinedmodel:41.4%); theprog-
nostic summary indexoutperformed clinicalmodels by 11.9%
in the CHR group (clinical model: 52.9%; combined model:
64.8%)and9.4%intheRODgroup(clinicalmodel:32.0%;com-
binedmodel: 41.4%). Furthermore, the sequential social func-
tioningprediction analysis showed that,with increasing clini-
cal model uncertainty (decision scores closer to the support
vector machines’ decision boundary), the prognostic sum-
mary index of the combinedmodel increased to 82.6% in the
group inCHRstates andwas stable (35%-50%) inpatientswith
ROD (eFigures 12 and 13 in the Supplement). Thus, in ambigu-
ouscases, combinedmodelsprovideda1.9-foldprognosticgain
for patients in the CHR state and a 10.5-fold prognostic gain
for patientswithROD comparedwith a purely clinical predic-
tion model that evaluated the patients' social and role func-
tioning at baseline and before study inclusion.
Finally, expert raters’ global functioning estimates
correctly identified the social functioning outcomes of par-
ticipants inCHRstateswithabalancedaccuracyof 71.8% (sen-
sitivity: 51.5%, specificity: 92.0%). Expert raters accurately
identifiedthesocial-functioningoutcomesforparticipantswith
ROD with a balanced accuracy of 59.6% (sensitivity: 26.6%;
specificity: 92.6%). The raters’ estimates correctly identified
role-functioningoutcomeswith abalancedaccuracyof 70.4%
Figure 1. Comparison of Functional Baseline and CombinedModel Signatures
Role Functioning, Current
Social Functioning, Current
Role Functioning, Highest in Past Year
Social Functioning, Highest in Past Year
Role Functioning, Lowest in Past Year
Social Functioning, Lowest in Past Year
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Social Functioning, Highest, Lifetime
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Social functioning in patients
in CHR state
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Role functioning in patients
in CHR state
B
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Social functioning in patients
with ROD
C
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Social functioning in patients
in CHR state
D
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Social functioning in patients
with ROD
E
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Role functioning in patients
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Clinical Model
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The predictive value of baseline global functioning scores used bymodels with
significant associations with functional outcomes wasmeasured in terms of the
variable selection frequency across all the support-vector machinemodels
generated in the nested leave-site-out cross-validation experiment. A value of 1
indicates that all models had retained the given variable during sequential
backward feature elimination. Horizontal bar plots show the variable selection
profiles of the clinical models making predictions of social functioning scores (A)
and role functioning scores (B) in the group in the clinical high-risk (CHR) state
and themodel trained on social functioning scores from patients with
recent-onset depression (ROD) (C), with orange lines at 0.5, which equals 50%
of support-vector machinemodels’ selected given variable. Reliability profiles of
the combined social functioningmodel, trained in the patients in CHR states (D)
and patients with ROD (E) and a reliability profile model trained on role
functioning scores from patients with ROD (F), with orange lines at a
cross-validation ratio of 2, which indicates 95% confidence in the reliable
involvement of given variable in themodel's decision rule. MRI indicates
magnetic resonance imaging.
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(sensitivity:49.3%;specificity:91.5%) forpatients inCHRstates
and a balanced accuracy of 57.9% (sensitivity: 25.0%; speci-
ficity: 90.7%) for patients with ROD. Thus, the raters under-
estimated the risk of impairment in social and role function-
ing inpatients inCHRstatesandpatientswithRODat follow-up
(Table 2). Models outperformed raters in all predictive tasks
(Table 2 and eTable 9 in the Supplement) and were not influ-
enced by the patients’ age, sex, or ethnicity (eTable 13 in the
Supplement).
Transdiagnostic Prognostic Generalization
In the CHR group, a poor social functioning prognosis as pro-
vided by the clinical predictionmodelwas associatedwith an
increasedprevalenceofDSM-IV-TRdiagnoses at follow-up: 13
of49patients inCHRstates (27.1%)withpoorprognoses (eTable
10 in the Supplement) had a major depressive disorder at
follow-up, compared with 0% in the group with a good prog-
nosis (χ21 = 15.8;P < .001).Hence, in thesepatients, the clinical
prediction model projected a major depressive disorder at fol-
low-up with a balanced accuracy of 79.5% (P < .001; eTable 10
in the Supplement). Similarly, 25 of 49 patients in CHR states
(51%)who had poor prognoses had at least 1DSM-IV-TRmood,
anxiety, or substance use disorder, compared with 6 of the 52
patients inCHRstates(11.5%)whohadgoodprognoses(χ21 = 18.5;
P < .001;balancedaccuracy, 73.2%;P = .03).Theclinicalmodel
predictingsocial functioningsignificantlygeneralizedtothepre-
diction of these diagnostic outcomes (eTable 10 in the Supple-
ment). However, only the sMRI model consistently assigned a
poor social functioning prognosis to the patients who transi-
tioned to psychosis (balanced accuracy, 72.7%; P = .01), result-
Figure 2. Comparison of Predictive Neuroanatomical Baseline Signatures in Patient Groups,
Detected by the Structural Magnetic Resonance Imaging–BasedModel
Clinically high-risk state groupA Recent-onset depression groupB
2 Cross-Validation Ratio
Impaired ➞ Good
Good ➞ Impaired
8
The reliability of predictive voxels in
significant models was measured via
a cross-validation ratio map with a
threshold of ± 2, which corresponded
to an α level of .05. Color scales
indicate increased vs decreased gray
matter volume in individuals in the
clinical high-risk state or with
recent-onset depression whowere
impaired on follow-up, compared
with patients with no impairment on
follow-up. The open-source
3-dimensional rendering software
MRIcroGL (McCausland Center for
Brain Imaging, University of South
Carolina; https://www.nitrc.org
/projects/mricrogl/) was used to
overlay the cross-validation ratio
maps on theMontreal Neurological
Institute single-participant template
and produce 3-dimensional
renderings and axial mosaic slices.
The cool color scale indicates
increased gray matter volume and
the warm color scale reduced gray
matter volume in individuals in
clinical high-risk states or with
recent-onsent depression whowere
impaired on follow-up, compared
with patients with no impairment at
follow-up.
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ing in a transition risk of 11.9% for thosewithpoorprognoses (8
of67)vs0%inthosewithprognosesofgoodoutcomes(χ21 = 6.28;
P = .02). InpatientswithROD,social functioningpredictionsdid
not generalize to diagnostic outcomes.
Discussion
Persistent social and role functioning deficits drive the per-
sonal and socioeconomic burden of psychotic and mood
disorders.41 Yet mental health care lacks the computational
tools that could enable the early recognition of these deficits
in help-seeking patients.42,43 Suchprognostic toolsmay cata-
lyze the development of novel biobehavioral therapies for in-
dividualized secondary and tertiary prevention.4,44-47 In this
article, we report on what is to our knowledge the first inter-
national effort todevelop such tools for thepredictionof func-
tional outcomes in young patients at risk for psychosis or
recurrent depression.48 Via thoroughly cross-validated ma-
chine-learningmethods,we found that social functioning im-
pairments can be correctly predicted in up to 83% of patients
in CHR states and 70% of patients with ROD who were
recruited from community-based and hospital-based path-
ways to care across geographically distinct European popula-
tions. These results suggest that the individualized quantifi-
cationof risk for impairedfunctional recovery is feasibledespite
site-associatedheterogeneityandevenwithoutaprestudycali-
bration of sMRI procedures. Additionally, our inclusive study
protocol running in clinical early recognition services facili-
tated the prognostic algorithms’ derivation and validation in
patients representing someof the real-world diversity of CHR
states forpsychosis,depression,andcomorbidpsychiatric con-
ditions. In this realistic test bed of model generalizability, we
observed that role functioningwas less clearly associatedwith
predictors than social functioning when analyzed functional
baseline data was used and was even less so when structural
neuroimaging data was used. Role functioning may be more
strongly determined by concurrent environmental and clini-
cal factors than social deficits, leading to a greater degree of
temporal fluctuation, which in turn potentially mediates dif-
ferential associationswithbaselineclinical andneuroanatomi-
cal predictors (eFigure4 in theSupplement).28,49,50 Future re-
search should therefore assess whether the inclusion of
environmental and clinical variables may improve the asso-
ciation with outcomes of role functioning deficits in similar
help-seeking populations.
Importantly,weobserved that combinedmodels integrat-
ingclinicalandbrainstructuraldataoutperformedhumanclini-
cal raters, suggestingthat thesemodelscould improvetheprog-
nostic process beyond the current level. Interestingly, clinical
raters overestimated patients’ social functioning improve-
ment, particularly in theRODgroup, inwhich only 27%of pa-
tients who ultimately experienced impaired outcomes were
correctly identified.Anadditional sensitivity analysis showed
that raters performed better in patients with ROD when im-
paired social functioningwas categorized at lower cutoff val-
ues, suggesting that prognostic reasoning is sensitive tomore
severe functionaldeficits at follow-up (eTable 14 in theSupple-
ment). In the group in CHR states, however, raters prognosti-
cated best at the original cutoff levels but were less accurate
than our machine learning models. This observation sug-
gests that internal heuristics, which are potentially informed
by the study groups’ differing clinical profiles, may influence
clinicians’ prognostication. Taken together, rater-basedprog-
nostication may considerably overestimate vulnerable pa-
tients’ capacity to recover fromsocial functioningdeficits.Fur-
ther research is needed to understand the factors governing
functional prognostication in psychiatry to design algo-
rithms that optimally mitigate prognostic bias.
The comparisons of models revealed that combined risk
stratification generally outperformed unimodal prediction
models. Despite the benefits of combined predictionmodels,
however,ourclinicalmodelsevaluatingonly8functioningvari-
ables would provide a cost-effective first-line strategy for
estimating the riskof future social disability similar to thepsy-
chosis, depression, and suicide risk calculators recently pro-
posed for secondary andoutpatient care.12,21,23,51 In the group
withCHRstates,wewere able to show that our functional risk
calculatornotonlyestimated future social impairmentbutalso
broader psychiatricmorbidity (eTable 10 in the Supplement).
These findingswere corroborated by the observation that pa-
tients in CHR stateswith anMRI-based prognosis of impaired
social functioning experiencedunremitting symptoms, occu-
pational disability, and poor quality of life (eFigure 10 in the
Supplement). Thus, risk calculators for social impairmentmay
provide accessible tools for a more generalized psychiatric
risk screening for individuals in theCHRstate. In contrast, the
models specific to patients with ROD did not show a compa-
rable prognostic generalizability. This discrepancy may
alignwith recent findings revealing pronounced social cogni-
tion deficits in individuals with psychosis vs individuals
with depression,52 and a close link between psychiatric mor-
bidity, social functioning, and social cognitive processes in
psychosis.53-55
BecauseMRI iscost intensive,weexploredwhethersequen-
tial predictive modeling could provide a rationale for the tar-
geted use of structural neuroimaging (eFigures 12 and 13 in the
Supplement). We observed pronounced benefits of blending
sMRI and functional data inpatientswith increasingly ambigu-
ous clinical decision scores, suggesting that the cost-benefit ra-
tio of sMRI can be maximized by including it at a later, more
elaborated stage of the prognostic workflow. Notably, thismay
includetheassessmentoftransitionriskbasedonthefindingthat
onlythesMRI-basedmodelpredictingsocial functioningshowed
significantprognosticgeneralizability in this context (eTable 10
in the Supplement). Taken together, these resultsmay provide
a first empirical account of prognostic improvements brought
about by sequential multimodal risk assessment.30 Future
studiesshouldassess theaddedvalueofdifferentdatacombina-
tions, includingneurocognition,18,56electroencephalography,20
sensor-basedactivitypatterns,32andlanguagepatterns,57aswell
asmultiomics information.58
We observed striking differences between the neuroana-
tomical patterns associated with different social-functioning
outcomes in thepatients in theCHRstateand thepatientswith
ROD. Inpatients in theCHRstate, impaired functioningwasas-
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sociatedwithGMValterationsthat representedadeviationfrom
normalbrainvariationandthatmappedtothesaliencenetwork,59
the perisylvian language-associated system, the default-mode
network, and the central executivenetwork.60 SimilarGMVre-
ductions have been previously described in studies comparing
theCHR,first-episodepsychosis,andrelapsingstagesofpsycho-
sis with healthy control participants.61,62 Longitudinal data
pointedtoalteredneurodevelopmentaltrajectoriesofthesebrain
systems, suggesting a disturbed process of cortical reorganiza-
tionindifferentstagesofpsychosisdevelopment.63-67Structural
dysmaturationaffecting thesebrain systemsmay influence the
capacity toswitchbetweenself-referential thinking, salienceat-
tribution, andexecutive functioning,68,69 thusdisruptingcom-
plexprocessesof social cognitionandbehavior, and finallypre-
disposing to poor functional outcomes of the CHR state.53
In contrast, impaired social functioning in the groupwith
RODwasassociatedwithextendedprefrontal, insular, and lat-
eral temporal GMV increments. This pattern also differenti-
ated patients from healthy control participants. Brain vol-
umereductions focusedonthemedial temporal lobe, thedorsal
anterior cingulate cortex, and temporooccipital cortices.While
these abnormalities have been associated with earlier dis-
ease onset and poor outcomes of patients with major
depression,70 findings in prefrontal and temporal areas have
remained equivocal; for example, a recent VBM meta-
analysis ofRODreported increased insular, thalamic, and tem-
poral brainvolumesanddecreaseddorsolateral prefrontal cor-
tical volumes.71 However, extended insular and prefrontal
volumereductionswereparticularly found inpatientswith re-
lapsingdepression andearly disease onset.72,73 Togetherwith
our findings, thismaypoint todynamic brain volumechanges
with potentially insufficient prefrontal compensatory pro-
cesses in patients with RODwho fail to recover.
These largelynonoverlappingneuroanatomicalpatternsof
impairedsocial functioningoutcomeexplainthe lowMRImodel
transferabilitybetweenthe2diagnosticgroups.Thisfindingchal-
lengesthehypothesisofsharedbrainsurrogatesunderlyingtrans-
diagnosticphenotypes, suchas theSystemsforSocialProcesses
domainproposedbytheNational InstituteofMentalHealth’sRe-
search Domain Criteria.74 Alternatively, the recently revealed
brain-behavioralheterogeneityofdepression75mayhaveimpeded
our algorithms from detecting a salient and thus generalizable
neuroanatomicalsignatureofsocialfunctioningintheRODgroup
and/or reducedthegeneralizabilityof theCHR-specificmodel to
anumbrella constructofdepression.Thesealternativehypoth-
eses call for more research using subtyping strategies76 to test
whether the current neurobiological and outcome-associated
heterogeneity ofmental disorders can be deconvolved into pa-
tient stratawith distinct prognostic profiles.
Limitations
One limitationmaybe thedichotomizationof the global func-
tioning scales and the use of classificationmodels for predic-
tion.Regression requires a sufficient representationof the tails
in the target scale to learn a predictive pattern explaining the
scale’s full range. Because this requirement was not met by
our data (eFigure 3 in the Supplement), we preferred classifi-
cation to regression models. Notably, based on the high
correlation between the patients’ ordinal social functioning
follow-up scores and theoutcomeprobability estimates of the
combinedmodels asssessing social functioning (Table 2), we
tested whether post hoc regression models could success-
fullymaptheseestimates to theglobal functioningscore range.
The lowmeanaverageerrors of thesemodels (eFigure 11 in the
Supplement) suggest that continuous targets couldbeapproxi-
mated through soft classification.
Conclusions
In summary, we identified generalizable clinical, imaging-
based, and combined prediction models of persistent social
functioning impairments in young patients at increased risk
for psychosis and recurrent depression. To further elucidate
the clinical, environmental, and neurobiological factors that
facilitate or limit the transferability of the risk calculators
presentedhere, external andprospective validation is needed
in ethnically diverse patient populations recruited at sites be-
yond the European catchment areas of this study. This is the
next important step towardquantifying the feasibility andutil-
ity of precision psychiatry approaches for the secondary and
tertiary prevention of severe mental illnesses.
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